(Total Views: 781)
Posted On: 03/16/2020 2:24:17 AM
Post# of 9144
https://www.youtube.com/watch?v=zMRrNY0pxfM
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
(4)
(0)
